Substudy 1: A Phase 2, Umbrella Study with Rolling Arms of Investigational Agents with Pembrolizumab in Combination with Chemotherapy in Treatment-Naive Patients with Advanced Non-small Cell Lung Cancer (NSCLC)

Grants and Contracts Details

StatusActive
Effective start/end date2/4/20 → 6/2/24

Funding

  • Merck Sharp & Dohme Corporation: $239,360.00